Open-mkt buys · 90d
$1.68M
2 trades · 2 insiders
Open-mkt sales · 90d
$2.13M
6 trades · 2 insiders
Net · 90d
$-451.7K
Insiders on file
37
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer | 5 | $559.7K | $0 | 2026-10-15 |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | 82 | $1.20M | $24.82M | 2026-09-30 |
| Svoronos Dawn | Director | 22 | $141.0K | $967.5K | 2026-09-01 |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | 21 | $20.2K | $1.12M | 2026-08-28 |
| GANNON STEVEN | Director | 29 | $42.3K | $1.88M | 2026-08-11 |
| Cannon Gillian | Director | 9 | $0 | $63.2K | 2026-06-05 |
| PATOU GARY | Director | 70 | $35.9K | $1.48M | 2026-06-05 |
| GAROFALO ELIZABETH A. | Director | 14 | $0 | $95.6K | 2026-06-03 |
| Gover Justin D. | Director | 8 | $0 | $0 | 2026-06-03 |
| Machado Patrick | Director | 11 | $0 | $0 | 2026-06-03 |
| DiFabio Andrea | Chief Legal Officer | 14 | $0 | $230.8K | 2026-03-13 |
| Cline Darren S | Chief Commercial Officer | 3 | $0 | $0 | 2026-01-09 |
| AULIN SHERRY | Chief Financial Officer | 24 | $0 | $1.38M | 2024-12-18 |
| Von Seggern Christopher | Chief Commercial Officer | 6 | $97.6K | $0 | 2024-03-11 |
| EMPFIELD JAMES R. | SVP, Drug Discovery | 30 | $24.8K | $3.78M | 2024-03-11 |
| ROBIN SHERRINGTON | SVP Bus. & Corp. Development | 70 | $0 | $3.61M | 2024-03-11 |
| AZAB MOHAMMAD | Director | 39 | $81.2K | $214 | 2023-12-19 |
| PIMSTONE SIMON N. | President, CEO and Director | 103 | $17.4K | $15.04M | 2023-06-02 |
| Hayden Michael R | Director | 47 | $41.3K | $0 | 2021-06-03 |
| HOLLER FRANK A | Director | 51 | $0 | $883.8K | 2021-05-27 |
| TARNOW MICHAEL M | Director | 57 | $0 | $0 | 2021-05-18 |
| Desjardins Clarissa | Director | 2 | $0 | $0 | 2020-06-01 |
| AYCARDI-FONSECA ERNESTO | Chief Medical Officer | 3 | $0 | $0 | 2020-03-12 |
| SCHELLER RICHARD H | Director | 7 | $19.9K | $0 | 2019-09-16 |
| COHEN CHARLES J. | VP, Biology | 12 | $0 | $0 | 2018-12-11 |
| LAMPERT MARK N | 10% Owner | 12 | $81.6K | $0 | 2018-03-27 |
| GOLDBERG Y. PAUL | VP, Clinical Development | 41 | $0 | $196.7K | 2017-10-23 |
| WINQUIST RAYMOND | Head, Translational Research | 3 | $3.0K | $0 | 2017-08-18 |
| BIOTECHNOLOGY VALUE FUND II LP | Other | 4 | $157.1K | $0 | 2017-08-15 |
| BIOTECHNOLOGY VALUE FUND L P | Other | 3 | $259.8K | $0 | 2017-06-27 |
| BVF Partners OS Ltd. | Other | 3 | $341.8K | $0 | 2017-06-27 |
| BVF PARTNERS L P/IL | 10% Owner | 15 | $1.47M | $0 | 2017-06-19 |
| Evans Johnston L | Director | 4 | $0 | $0 | 2015-05-04 |
| STEIN EVAN A. | Director | 8 | $0 | $0 | 2015-04-30 |
| CORRAINI KAREN G. | Gen. Counsel & Corp. Secretary | 1 | $0 | $0 | 2015-03-17 |
| MX Associates, LLP | 10% Owner | 7 | $0 | $0 | 2014-12-31 |
| Bridger Gary | EVP, Research & Development | 1 | $0 | $0 | 2014-11-21 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Kelly Thomas Patrick | Chief Financial Officer | M Exercise deriv | 2026-10-15 | 2026-10-16 | 7,500 | — | $0 | 22,500 | SEC↗ |
| Kelly Thomas Patrick | Chief Financial Officer | M Exercise | 2026-10-15 | 2026-10-16 | 7,500 | — | — | 22,500 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO, Director | P Buy | 2026-09-30 | 2026-10-01 | 30,000 | $37.38 | $1.12M | 49,923 | SEC↗ |
| Kelly Thomas Patrick | Chief Financial Officer | P Buy | 2026-09-30 | 2026-10-01 | 15,000 | $37.32 | $559.7K | 15,000 | SEC↗ |
| Svoronos Dawn | Director | M Exercise deriv | 2026-09-01 | 2026-09-03 | 5,144 | — | $0 | 0 | SEC↗ |
| Svoronos Dawn | Director | M Exercise | 2026-09-01 | 2026-09-03 | 5,144 | $8.15 | $41.9K | 31,373 | SEC↗ |
| Svoronos Dawn | Director | M Exercise deriv | 2026-09-01 | 2026-09-03 | 5,144 | — | $0 | 0 | SEC↗ |
| Svoronos Dawn | Director | M Exercise | 2026-09-01 | 2026-09-03 | 5,144 | $8.15 | $41.9K | 31,373 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-08-28 | 2026-08-31 | 700 | $60.98 | $42.7K | 2 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-08-28 | 2026-08-31 | 6,368 | $60.17 | $383.2K | 702 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-08-28 | 2026-08-31 | 700 | $60.98 | $42.7K | 2 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-08-28 | 2026-08-31 | 6,368 | $60.17 | $383.1K | 702 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2026-08-11 | 2026-08-13 | 10,000 | $64.06 | $640.6K | 1,870 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2026-08-11 | 2026-08-13 | 10,000 | $64.06 | $640.5K | 1,870 | SEC↗ |
| Cannon Gillian | Director | S Sale | 2026-06-05 | 2026-06-08 | 1,190 | $53.14 | $63.2K | 1,455 | SEC↗ |
| PATOU GARY | Director | S Sale | 2026-06-05 | 2026-06-08 | 1,322 | $53.14 | $70.3K | 24,896 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 10,507 | — | $0 | 10,507 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2026-06-03 | 2026-06-03 | 1,593 | — | $0 | 1,593 | SEC↗ |
| Svoronos Dawn | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| Cannon Gillian | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| GANNON STEVEN | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| Gover Justin D. | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| Machado Patrick | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 0 | SEC↗ |
| Svoronos Dawn | Director | F Tax w/h | 2026-06-01 | 2026-06-03 | 1,416 | $53.41 | $75.6K | 26,229 | SEC↗ |
| Svoronos Dawn | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 27,645 | SEC↗ |
| Cannon Gillian | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 2,645 | SEC↗ |
| GANNON STEVEN | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 13,286 | SEC↗ |
| GANNON STEVEN | Director | F Tax w/h | 2026-06-01 | 2026-06-03 | 1,416 | $53.41 | $75.6K | 11,870 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 2,645 | SEC↗ |
| Gover Justin D. | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 2,645 | SEC↗ |
| Machado Patrick | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 2,645 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2026-06-01 | 2026-06-03 | 2,645 | — | $0 | 26,218 | SEC↗ |
| GANNON STEVEN | Director | M Exercise deriv | 2026-05-12 | 2026-05-13 | 3,500 | — | $0 | 0 | SEC↗ |
| GANNON STEVEN | Director | M Exercise | 2026-05-12 | 2026-05-13 | 3,500 | $7.38 | $25.8K | 10,641 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-13 | 2026-03-13 | 7,308 | $55.23 | $403.6K | 19,923 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | S Sale | 2026-03-13 | 2026-03-13 | 1,342 | $55.23 | $74.1K | 7,301 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-03-13 | 2026-03-13 | 1,410 | $55.23 | $77.9K | 7,069 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-12 | 2026-03-13 | 12,500 | — | $0 | 37,500 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | M Exercise deriv | 2026-03-12 | 2026-03-13 | 3,750 | — | $0 | 11,250 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M Exercise deriv | 2026-03-12 | 2026-03-13 | 3,750 | — | $0 | 11,250 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-12 | 2026-03-13 | 12,500 | — | $0 | 27,231 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | M Exercise | 2026-03-12 | 2026-03-13 | 3,750 | — | $0 | 8,643 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M Exercise | 2026-03-12 | 2026-03-13 | 3,750 | — | $0 | 8,479 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-10 | 2026-03-11 | 11,269 | $60.11 | $677.4K | 14,731 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | S Sale | 2026-03-10 | 2026-03-11 | 2,607 | $60.11 | $156.7K | 4,893 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2026-03-10 | 2026-03-11 | 2,771 | $60.11 | $166.6K | 4,729 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-09 | 2026-03-11 | 25,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2026-03-09 | 2026-03-11 | 20,000 | — | $0 | 20,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-09 | 2026-03-11 | 20,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-09 | 2026-03-11 | 105,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-09 | 2026-03-11 | 75,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-03-09 | 2026-03-11 | 65,000 | — | $0 | 0 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 7,500 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | M Exercise deriv | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 0 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 7,500 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M Exercise deriv | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-09 | 2026-03-11 | 20,000 | — | $0 | 26,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 65,000 | $62.06 | $4.03M | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-09 | 2026-03-11 | 65,000 | $9.44 | $613.6K | 71,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 61,652 | $60.08 | $3.70M | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 43,348 | $59.26 | $2.57M | 72,652 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-09 | 2026-03-11 | 105,000 | $4.75 | $498.8K | 111,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 2,449 | $61.26 | $150.0K | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 10,072 | $60.47 | $609.1K | 8,449 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 12,479 | $59.50 | $742.5K | 18,521 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-09 | 2026-03-11 | 25,000 | $3.10 | $77.5K | 31,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 21,515 | $60.49 | $1.30M | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 31,694 | $59.88 | $1.90M | 27,515 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-03-09 | 2026-03-11 | 21,791 | $58.81 | $1.28M | 59,209 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-03-09 | 2026-03-11 | 75,000 | $8.40 | $630.0K | 81,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | M Exercise | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 7,500 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | M Exercise | 2026-03-09 | 2026-03-11 | 7,500 | — | $0 | 7,500 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2026-01-09 | 2026-01-09 | 350,000 | — | $0 | 350,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2026-01-09 | 2026-01-09 | 65,000 | — | $0 | 65,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 80,000 | — | $0 | 80,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Cline Darren S | Chief Commercial Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Cline Darren S | Chief Commercial Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 20,000 | — | $0 | 20,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2026-01-09 | 2026-01-09 | 20,000 | — | $0 | 20,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2026-01-02 | 2026-01-02 | 40,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-01-02 | 2026-01-02 | 2,062 | $44.93 | $92.6K | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2026-01-02 | 2026-01-02 | 40,000 | $7.49 | $299.6K | 46,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2026-01-02 | 2026-01-02 | 37,938 | $44.40 | $1.68M | 8,062 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-12-08 | 2025-12-09 | 8,820 | $45.59 | $402.1K | 8,010 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-12-08 | 2025-12-09 | 2,010 | $46.32 | $93.1K | 6,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-12-05 | 2025-12-09 | 14,375 | $45.03 | $647.3K | 16,830 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-11-28 | 2025-12-03 | 97 | $45.01 | $4.4K | 31,205 | SEC↗ |
| Kelly Thomas Patrick | Chief Financial Officer | A Award deriv | 2025-10-15 | 2025-10-17 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Kelly Thomas Patrick | Chief Financial Officer | A Award deriv | 2025-10-15 | 2025-10-17 | 225,000 | — | $0 | 225,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | M Exercise deriv | 2025-10-01 | 2025-10-01 | 25,000 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | M Exercise | 2025-10-01 | 2025-10-01 | 25,000 | $7.69 | $192.3K | 56,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO | S Sale | 2025-10-01 | 2025-10-01 | 25,000 | $40.16 | $1.00M | 31,302 | SEC↗ |
| Cline Darren S | Chief Commercial Officer | A Award deriv | 2025-06-23 | 2025-06-24 | 185,800 | — | $0 | 185,800 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 2,645 | — | $0 | 2,645 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2025-06-05 | 2025-06-06 | 17,012 | — | $0 | 17,012 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2025-06-05 | 2025-06-06 | 3 | $30.48 | $91 | 7,141 | SEC↗ |
| GANNON STEVEN | Director | M Exercise deriv | 2025-05-14 | 2025-05-16 | 5,144 | — | $0 | 0 | SEC↗ |
| GANNON STEVEN | Director | M Exercise | 2025-05-14 | 2025-05-16 | 5,144 | $12.57 | $64.7K | 7,144 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2025-03-12 | 2025-03-13 | 80,000 | — | $0 | 80,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2025-03-12 | 2025-03-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2025-03-12 | 2025-03-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2025-03-12 | 2025-03-13 | 80,000 | — | $0 | 80,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2025-03-12 | 2025-03-13 | 50,000 | — | $0 | 50,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2025-03-12 | 2025-03-13 | 275,000 | — | $0 | 275,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2025-01-27 | 2025-01-27 | 16,315 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2025-01-27 | 2025-01-27 | 15,166 | $17.76 | $269.3K | 46,468 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-01-27 | 2025-01-27 | 1,149 | $41.07 | $47.2K | 31,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-01-27 | 2025-01-27 | 15,166 | $40.46 | $613.6K | 31,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2025-01-27 | 2025-01-27 | 1,149 | $17.76 | $20.4K | 32,451 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2025-01-24 | 2025-01-27 | 22,468 | — | $0 | 16,315 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-01-24 | 2025-01-27 | 22,468 | $40.20 | $903.2K | 31,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2025-01-24 | 2025-01-27 | 22,468 | $17.76 | $399.0K | 53,770 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2025-01-23 | 2025-01-27 | 16,217 | — | $0 | 38,783 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2025-01-23 | 2025-01-27 | 16,217 | $40.08 | $650.0K | 31,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2025-01-23 | 2025-01-27 | 16,217 | $17.76 | $288.0K | 47,519 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2024-12-18 | 2024-12-19 | 9,334 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2024-12-18 | 2024-12-19 | 16,000 | — | $0 | 6,000 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | S Sale | 2024-12-18 | 2024-12-19 | 7,199 | $41.23 | $296.8K | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | S Sale | 2024-12-18 | 2024-12-19 | 11,510 | $41.19 | $474.1K | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2024-12-18 | 2024-12-19 | 9,334 | $9.44 | $88.1K | 9,334 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2024-12-18 | 2024-12-19 | 16,000 | $11.58 | $185.3K | 16,000 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | F Tax w/h | 2024-12-18 | 2024-12-19 | 4,490 | $41.28 | $185.3K | 11,510 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | F Tax w/h | 2024-12-18 | 2024-12-19 | 2,135 | $41.28 | $88.1K | 7,199 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2024-11-22 | 2024-11-22 | 3,086 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2024-11-22 | 2024-11-22 | 3,500 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | S Sale | 2024-11-22 | 2024-11-22 | 2,851 | $41.11 | $117.2K | 23,573 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2024-11-22 | 2024-11-22 | 1,046 | $39.80 | $41.6K | 25,613 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2024-11-22 | 2024-11-22 | 3,086 | $13.48 | $41.6K | 26,659 | SEC↗ |
| PATOU GARY | Director | S Sale | 2024-11-22 | 2024-11-22 | 2,040 | $41.05 | $83.7K | 23,573 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2024-11-22 | 2024-11-22 | 649 | $39.80 | $25.8K | 26,424 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2024-11-22 | 2024-11-22 | 3,500 | $7.38 | $25.8K | 27,073 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2024-06-05 | 2024-06-05 | 15,542 | — | $0 | 15,542 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2024-03-11 | 2024-03-12 | 250,000 | — | $0 | 250,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2024-03-11 | 2024-03-12 | 100,000 | — | $0 | 100,000 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | A Award deriv | 2024-03-11 | 2024-03-12 | 65,000 | — | $0 | 65,000 | SEC↗ |
| EMPFIELD JAMES R. | EVP, Drug Discovery | A Award deriv | 2024-03-11 | 2024-03-12 | 65,000 | — | $0 | 65,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2024-03-11 | 2024-03-12 | 100,000 | — | $0 | 100,000 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | A Award deriv | 2024-03-11 | 2024-03-12 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Von Seggern Christopher | Chief Commercial Officer | A Award deriv | 2024-03-11 | 2024-03-12 | 100,000 | — | $0 | 100,000 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | M Exercise deriv | 2024-03-08 | 2024-03-11 | 3,500 | — | $0 | 16,500 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | F Tax w/h | 2024-03-08 | 2024-03-11 | 1,408 | $46.16 | $65.0K | 2,092 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | S Sale | 2024-03-08 | 2024-03-11 | 2,092 | $45.69 | $95.6K | 0 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | M Exercise | 2024-03-08 | 2024-03-11 | 3,500 | $18.56 | $65.0K | 3,500 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise deriv | 2024-03-07 | 2024-03-08 | 7,407 | — | $0 | 0 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise deriv | 2024-03-07 | 2024-03-08 | 1,234 | — | $0 | 0 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2024-03-07 | 2024-03-08 | 1,000 | $46.45 | $46.5K | 14,000 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2024-03-07 | 2024-03-08 | 2,000 | $46.20 | $92.4K | 2,000 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2024-03-07 | 2024-03-08 | 5,000 | $46.25 | $231.3K | 9,000 | SEC↗ |
| GANNON STEVEN | Director | S Sale | 2024-03-07 | 2024-03-08 | 5,000 | $46.30 | $231.5K | 4,000 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | S Sale | 2024-03-07 | 2024-03-08 | 1,019 | $46.15 | $47.0K | 14,516 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | F Tax w/h | 2024-03-07 | 2024-03-08 | 1,289 | $45.96 | $59.2K | 15,535 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | F Tax w/h | 2024-03-07 | 2024-03-08 | 215 | $45.96 | $9.9K | 9,417 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise | 2024-03-07 | 2024-03-08 | 1,234 | $9.85 | $12.2K | 9,632 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | S Sale | 2024-03-07 | 2024-03-08 | 6,118 | $46.30 | $283.3K | 8,398 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise | 2024-03-07 | 2024-03-08 | 7,407 | $9.85 | $73.0K | 16,824 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | J Other | 2023-12-29 | 2024-01-02 | 8,398 | — | $0 | 8,398 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise deriv | 2023-12-19 | 2023-12-20 | 823 | — | $0 | 0 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise deriv | 2023-12-19 | 2023-12-20 | 3,497 | — | $0 | 0 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise | 2023-12-19 | 2023-12-20 | 3,497 | $9.85 | $34.4K | 74,225 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise | 2023-12-19 | 2023-12-20 | 823 | $9.85 | $8.1K | 70,728 | SEC↗ |
| PATOU GARY | Director | S Sale | 2023-12-14 | 2023-12-15 | 7,598 | $41.05 | $311.9K | 4,902 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2023-12-13 | 2023-12-15 | 6,378 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2023-12-13 | 2023-12-15 | 2,800 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2023-12-13 | 2023-12-15 | 5,144 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | S Sale | 2023-12-13 | 2023-12-15 | 5,100 | $38.94 | $198.6K | 23,573 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2023-12-13 | 2023-12-15 | 6,378 | $9.85 | $62.8K | 29,951 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2023-12-13 | 2023-12-15 | 1,278 | $39.68 | $50.7K | 28,673 | SEC↗ |
| PATOU GARY | Director | S Sale | 2023-12-13 | 2023-12-15 | 7,598 | $41.05 | $311.9K | 4,902 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2023-12-13 | 2023-12-15 | 2,880 | $9.85 | $28.4K | 26,453 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2023-12-13 | 2023-12-15 | 577 | $39.68 | $22.9K | 25,876 | SEC↗ |
| PATOU GARY | Director | S Sale | 2023-12-13 | 2023-12-15 | 3,977 | $39.84 | $158.4K | 23,573 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2023-12-13 | 2023-12-15 | 1,167 | $39.68 | $46.3K | 27,550 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2023-12-13 | 2023-12-15 | 5,144 | $9.00 | $46.3K | 28,717 | SEC↗ |
| PATOU GARY | Director | S Sale | 2023-12-13 | 2023-12-15 | 2,303 | $39.10 | $90.0K | 23,573 | SEC↗ |
| Svoronos Dawn | Director | S Sale | 2023-08-24 | 2023-08-24 | 25,000 | $38.70 | $967.5K | 25,000 | SEC↗ |
| Cannon Gillian | Director | A Award deriv | 2023-08-10 | 2023-08-10 | 28,000 | — | $0 | 28,000 | SEC↗ |
| Gover Justin D. | Director | A Award deriv | 2023-08-10 | 2023-08-10 | 28,000 | — | $0 | 28,000 | SEC↗ |
| Machado Patrick | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| PIMSTONE SIMON N. | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| GAROFALO ELIZABETH A. | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| Svoronos Dawn | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| GANNON STEVEN | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| PATOU GARY | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| AZAB MOHAMMAD | Director | A Award deriv | 2023-06-02 | 2023-06-02 | 18,475 | — | $0 | 18,475 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-06-01 | 2023-06-01 | 45,000 | — | $0 | 0 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-06-01 | 2023-06-01 | 9,318 | — | $0 | 30,682 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-06-01 | 2023-06-01 | 24,255 | $38.78 | $940.6K | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-06-01 | 2023-06-01 | 20,745 | $38.53 | $799.3K | 30,255 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-06-01 | 2023-06-01 | 45,000 | $17.76 | $799.2K | 51,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-06-01 | 2023-06-01 | 7,458 | $38.97 | $290.6K | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-06-01 | 2023-06-01 | 1,860 | $38.53 | $71.7K | 13,458 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-06-01 | 2023-06-01 | 9,318 | $7.69 | $71.7K | 15,318 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-05-31 | 2023-06-01 | 29,835 | — | $0 | 0 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-05-31 | 2023-06-01 | 50,000 | — | $0 | 45,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-05-31 | 2023-06-01 | 26,856 | $38.69 | $1.04M | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-05-31 | 2023-06-01 | 23,144 | $38.37 | $888.0K | 32,856 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-05-31 | 2023-06-01 | 50,000 | $17.76 | $888.0K | 56,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-05-31 | 2023-06-01 | 23,670 | $38.81 | $918.6K | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-05-31 | 2023-06-01 | 6,165 | $38.37 | $236.6K | 29,670 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-05-31 | 2023-06-01 | 29,835 | $9.85 | $293.9K | 35,835 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-05-31 | 2023-06-01 | 12,000 | $38.53 | $462.4K | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-05-30 | 2023-06-01 | 18,006 | $38.63 | $695.6K | 37,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-05-30 | 2023-06-01 | 19,000 | $39.90 | $758.1K | 18,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2023-05-24 | 2023-05-26 | 42,592 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2023-05-24 | 2023-05-26 | 6,172 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise deriv | 2023-05-24 | 2023-05-26 | 20,576 | — | $0 | 0 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | F Tax w/h | 2023-05-24 | 2023-05-26 | 3,902 | $41.84 | $163.3K | 40,887 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2023-05-24 | 2023-05-26 | 42,592 | $9.44 | $402.1K | 48,592 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | F Tax w/h | 2023-05-24 | 2023-05-26 | 7,310 | $41.84 | $305.9K | 41,282 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2023-05-24 | 2023-05-26 | 6,172 | $9.85 | $60.8K | 33,880 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | F Tax w/h | 2023-05-24 | 2023-05-26 | 1,171 | $41.84 | $49.0K | 32,709 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | M Exercise | 2023-05-24 | 2023-05-26 | 20,576 | $9.85 | $202.7K | 44,789 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2023-05-24 | 2023-05-26 | 1,407 | $41.49 | $58.4K | 31,302 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2023-05-24 | 2023-05-26 | 13,179 | $41.37 | $545.2K | 27,708 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | S Sale | 2023-05-24 | 2023-05-26 | 17,069 | $41.44 | $707.3K | 24,213 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | S Sale | 2023-03-24 | 2023-03-24 | 700 | $35.01 | $24.5K | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | A Award deriv | 2023-03-10 | 2023-03-14 | 120,000 | — | $0 | 120,000 | SEC↗ |
| EMPFIELD JAMES R. | EVP, Drug Discovery | A Award deriv | 2023-03-10 | 2023-03-14 | 75,000 | — | $0 | 75,000 | SEC↗ |
| KENNEY CHRISTOPHER JOHN | Chief Medical Officer | A Award deriv | 2023-03-10 | 2023-03-14 | 120,000 | — | $0 | 120,000 | SEC↗ |
| MORTIMER IAN | PRESIDENT & CEO | A Award deriv | 2023-03-10 | 2023-03-14 | 380,000 | — | $0 | 380,000 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2023-03-10 | 2023-03-14 | 45,000 | — | $0 | 45,000 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | A Award deriv | 2023-03-10 | 2023-03-14 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Von Seggern Christopher | Chief Commercial Officer | A Award deriv | 2023-03-10 | 2023-03-14 | 90,000 | — | $0 | 90,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-03-07 | 2023-03-09 | 41,152 | — | $0 | 0 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise deriv | 2023-03-07 | 2023-03-09 | 30,864 | — | $0 | 0 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-03-07 | 2023-03-09 | 41,152 | $2.68 | $110.3K | 47,152 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-03-07 | 2023-03-09 | 10,990 | $37.01 | $406.7K | 34,002 | SEC↗ |
| PIMSTONE SIMON N. | Director | M Exercise | 2023-03-07 | 2023-03-09 | 30,864 | $2.59 | $79.9K | 64,866 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-03-07 | 2023-03-09 | 1,618 | $37.13 | $60.1K | 63,248 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2023-03-07 | 2023-03-09 | 8,242 | $36.94 | $304.5K | 55,006 | SEC↗ |
| PIMSTONE SIMON N. | Director | F Tax w/h | 2023-03-07 | 2023-03-09 | 2,160 | $37.13 | $80.2K | 44,992 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise deriv | 2022-12-12 | 2022-12-13 | 3,086 | — | $0 | 0 | SEC↗ |
| AZAB MOHAMMAD | Director | M Exercise | 2022-12-12 | 2022-12-13 | 3,086 | $2.68 | $8.3K | 69,905 | SEC↗ |
| PATOU GARY | Director | M Exercise deriv | 2022-11-25 | 2022-11-28 | 2,057 | — | $0 | 0 | SEC↗ |
| PATOU GARY | Director | M Exercise | 2022-11-25 | 2022-11-28 | 2,057 | $2.68 | $5.5K | 25,630 | SEC↗ |
| PATOU GARY | Director | F Tax w/h | 2022-11-25 | 2022-11-28 | 120 | $34.37 | $4.1K | 25,510 | SEC↗ |
| PATOU GARY | Director | S Sale | 2022-11-25 | 2022-11-28 | 1,937 | $34.79 | $67.4K | 23,573 | SEC↗ |
| PATOU GARY | Director | S Sale | 2022-11-23 | 2022-11-28 | 2,057 | $34.33 | $70.6K | 23,573 | SEC↗ |
| DiFabio Andrea | Chief Legal Officer | A Award deriv | 2022-11-07 | 2022-11-09 | 135,000 | — | $0 | 135,000 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2022-09-02 | 2022-09-07 | 813 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2022-09-02 | 2022-09-07 | 32 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2022-09-02 | 2022-09-07 | 9,000 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2022-09-02 | 2022-09-07 | 2,292 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise deriv | 2022-09-02 | 2022-09-07 | 6,511 | — | $0 | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2022-09-02 | 2022-09-07 | 32 | $7.49 | $240 | 9,032 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2022-09-02 | 2022-09-07 | 9,000 | $9.44 | $85.0K | 9,000 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | S Sale | 2022-09-02 | 2022-09-07 | 15,355 | $39.57 | $607.6K | 0 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2022-09-02 | 2022-09-07 | 813 | $8.40 | $6.8K | 9,845 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | F Tax w/h | 2022-09-02 | 2022-09-07 | 3,293 | $39.53 | $130.2K | 15,355 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2022-09-02 | 2022-09-07 | 6,511 | $4.75 | $30.9K | 18,648 | SEC↗ |
| AULIN SHERRY | Chief Financial Officer | M Exercise | 2022-09-02 | 2022-09-07 | 2,292 | $3.10 | $7.1K | 12,137 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise deriv | 2022-09-01 | 2022-09-02 | 50,000 | — | $0 | 0 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | S Sale | 2022-09-01 | 2022-09-02 | 35,103 | $38.03 | $1.33M | 25,572 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | F Tax w/h | 2022-09-01 | 2022-09-02 | 6,121 | $38.81 | $237.6K | 60,675 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | S Sale | 2022-09-01 | 2022-09-02 | 8,776 | $38.80 | $340.5K | 16,796 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise | 2022-09-01 | 2022-09-02 | 50,000 | $4.75 | $237.5K | 66,796 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise deriv | 2022-08-31 | 2022-09-02 | 17,488 | — | $0 | 0 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise deriv | 2022-08-31 | 2022-09-02 | 5,000 | — | $0 | 0 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | S Sale | 2022-08-31 | 2022-09-02 | 21,352 | $38.57 | $823.5K | 16,796 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise | 2022-08-31 | 2022-09-02 | 17,488 | $2.67 | $46.7K | 34,720 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | M Exercise | 2022-08-31 | 2022-09-02 | 5,000 | $4.75 | $23.8K | 39,720 | SEC↗ |
| ROBIN SHERRINGTON | EVP, Strategy & Innovation | F Tax w/h | 2022-08-31 | 2022-09-02 | 1,572 | $37.86 | $59.5K | 38,148 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2022-08-16 | 2022-08-16 | 20,000 | $38.87 | $777.4K | 6,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2022-08-16 | 2022-08-16 | 32,058 | $38.29 | $1.23M | 26,000 | SEC↗ |
| PIMSTONE SIMON N. | Director | S Sale | 2022-08-15 | 2022-08-16 | 33,942 | $37.76 | $1.28M | 58,058 | SEC↗ |
| EMPFIELD JAMES R. | EVP, Drug Discovery | M Exercise deriv | 2022-08-12 | 2022-08-16 | 20,000 | — | $0 | 0 | SEC↗ |
| EMPFIELD JAMES R. | EVP, Drug Discovery | M Exercise deriv | 2022-08-12 | 2022-08-16 | 45,000 | — | $0 | 0 | SEC↗ |